The Prolastin Direct® program benefits

Comprehensive, personalized alpha-1 support for patients and physicians and their practices

When you prescribe PROLASTIN-C, you and your patients gain immediate access to all the benefits of the PROLASTIN DIRECT program. Call 1-800-305-7881 to speak with a Patient Service Coordinator.

One dedicated PROLASTIN-C coordinator1

  • One dedicated PROLASTIN-C coordinator specifically assigned to support you and your patients1:
    • Designed to simplify the process with one source for every alpha-1 need
    • >90% success obtaining insurance coverage for PROLASTIN-C
    • 98.4% treatment compliance rate for patients enrolled in the PROLASTIN DIRECT program1
  • Just 1 number connects you and your patients to a devoted Alpha-1 Care Team
    • Call 1-800-305-7881 to speak with a Patient Service Coordinator

See how the PROLASTIN DIRECT program simplifies the process— from enrollment to therapy to ongoing support.

Insurance Specialists and the Assist $0 copay program1

  • >90% success rate in obtaining patient coverage1
  • Hands on management of prior authorization process
  • PROLASTIN DIRECT will identify patients in need of financial assistance who are eligible to enroll in the Assist $0 copay program – providing up to $6600 every year

See how the PROLASTIN DIRECT program insurance and reimbursement specialists can help secure coverage.

24/7 on-call support1

  • Your PROLASTIN DIRECT Alpha-1 Care Team's Specialty Pharmacy and Infusion Experts:
    • 24/7 on-call support from specially trained registered nurses and pharmacists dedicated exclusively to alpha-1 care1
    • Provide access to a dedicated pharmacy that coordinates shipments, scheduling, and supply needs
    • Coordinate infusion therapy at a time that's convenient to your patient— at home, at a clinic, or when traveling — at no additional cost to the patient when insurance allows
  • Patients enrolled in the PROLASTIN DIRECT program have a compliance rate of 98.4%

Learn more about the support and infusion coordination provided by the PROLASTIN DIRECT program.

Automatic enrollment in a disease-management program1

  • Patients are automatically enrolled in a disease-management program (AlphaNet®)1:
    • One-on-one support from an experienced alpha-1 patient1
    • Proven outcomes in addition to augmentation therapy alone1,2
      • Increased compliance with prescribed COPD interventions
      • 10% reduction in exacerbations
      • 21% reduction in ER visits

Learn about how ADMAPP from the PROLASTIN DIRECT program may help your patients.

Partners

Grifols

Grifols, the manufacturer of PROLASTIN-C, is a global healthcare company, founded in 1940, whose mission is to improve the health and well-being of people around the world.

The PROLASTIN DIRECT program and Dohmen Life Science Services

Dohmen Life Science Services manages the PROLASTIN DIRECT program. A patient-centered service organization composed of pharmacy, insurance, and home healthcare experts, this fully dedicated specialty alpha-1 pharmacy provides your practice and your patients with administrative, clinical, and financial support.

PROLASTIN-C is available exclusively through PROLASTN DIRECT.

AlphaNet

AlphaNet is a not-for-profit organization of Alphas Serving Alphas®. A team of expert AlphaNet coordinators, all alphas themselves, are devoted to helping improve the lives of alphas receiving treatment with PROLASTIN-C.

 


PROLASTIN-C is available only through the PROLASTIN DIRECT program.


PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use


  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trial
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.


References

  1. Data on file, PROLASTIN DIRECT program.
  2. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.